These findings suggest that SA needs to be cautiously used in patients with obesity or diabetes, as SA-induced renal dysfunction may be exacerbated due to impaired TRPV1 in obese and diabetic patients. This evidence concerns the gene TRPV1 and obesity due to melanocortin 4 receptor deficiency.